632 related articles for article (PubMed ID: 25875256)
1. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
2. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
6. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
7. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
[TBL] [Abstract][Full Text] [Related]
9. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
10. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
[TBL] [Abstract][Full Text] [Related]
14. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
17. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
18. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
19. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Genovese MC; Jarosova K; Cieślak D; Alper J; Kivitz A; Hough DR; Maes P; Pineda L; Chen M; Zaidi F
Arthritis Rheumatol; 2015 Jul; 67(7):1703-10. PubMed ID: 25779750
[TBL] [Abstract][Full Text] [Related]
20. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
